Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 ( LOUISVILLE Colo. June 26 2007 /PRNe...)

Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839

LOUISVILLE, Colo., June 26, 2007 /PRNewswire-FirstCall/ -- Replidyne, Inc. today announced results from three Phase I trials studying REP8839, a novel topical antibiotic that has shown potent in vitro activity against major skin pathogens including methicillin-resistant S. aureus (MRSA). The results of the Phase I trials show that topically applied REP8839 appears safe, well-tolerated and associated with low systemic exposure, or drug absorption into the bloodstream, which is desirable for a topical antibiotic treatment. Based on these results, Replidyne plans to initiate Phase II trials in children with impetigo, the most common bacterial skin infection, by the end of the year.

"REP8839 is a promising development candidate and has the potential to be an important treatment option for physicians in the ongoing fight against drug-resistant infections including MRSA, a growing public health concern," said Kenneth J. Collins, Replidyne's President and Chief Executive Officer. "With these safety data, we intend to move forward into Phase II trials to study the safety and efficacy of REP8839 in patients with impetigo and other skin and wound infections."

REP8839 was tested in three Phase I trials which collectively enrolled over 400 subjects. In the first Phase I trial, safety, tolerability and skin irritancy were tested following repeated daily application of REP8839, at three drug concentrations (1%, 2% and 4%), on intact and abraded skin. Irritancy scores comparable to placebo were recorded for all REP8839 exposed test subjects. In the second study, in addition to safety, tolerability and dermal irritancy, systemic exposure was examined following repeated daily application of REP8839 on a larger surface area of intact and abraded skin. In all subjects, REP8839 was associated with low systemic exposure and low skin irritancy. In the third study, a 2% formulation of REP8839 was tested for its ability
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Replidyne Phase II Pediatric Trial Meets Primary Objective
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:

(Date:5/24/2013)... 2013 In accordance with Rule 17.1 and Rule ... the United States Exchange Act, Echo Pharma Acquisition Limited ("Royalty ... Corporation (NYSE: ELN). Background On 2 ... offer for the entire of the issued and to be ... Offer"). On 20 May 2013, Royalty Pharma ...

(Date:5/23/2013)... WASHINGTON , May 23, 2013 Vanda Pharmaceuticals Inc. ... company has been named the 2013 Life Science Firm of ... (TCM). Vanda was honored at the TCM,s 25 ... Bethesda , Maryland. The Tech Awards Celebration recognizes the ... in Maryland and the surrounding regions. ...

(Date:5/23/2013)... 2013 Nephros, Inc. (OTC Bulletin Board: ... that develops and sells high performance liquid purification ultrafilters, ... In addition, the concurrent temporary reduction in exercise price ... 17, 2013. Nephros estimates that it will ... offering. A portion of the proceeds will be used ...

Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9 Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2 Nephros Announces Completion of Rights Offering 2 Nephros Announces Completion of Rights Offering 3 Nephros Announces Completion of Rights Offering 4

[0] Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements [0] Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland [0] Nephros Announces Completion of Rights Offering

... Pharmaceuticals, Inc. (NASDAQ: OPTR ) announced today ... antibiotics in two Phase 3 clinical trials exploring the ... adult patients with Clostridium difficile -associated diarrhea (CDAD) ... Clinical Infectious Diseases (CID). The analysis found ...

... 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... CMED ), a leading China-based advanced ... unaudited financial results for the first ... ("1Q FY2011") today.1 Q FY20 ...

Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin China Medical Technologies Reports First Fiscal Quarter Financial Results

(Date:5/24/2013)... KC and Monica Craichy, Founders of ... Their oldest sons, Kyle and Austin Craichy, will be kiteboarding ... several professional kiteboarders. , KC Craichy said he is excited ... come together such that virtually everyone who planned to be ... kite boarders will meet at Matheson Hammock Park and Beach ...

(Date:5/24/2013)... Mirena IUD lawyers at the Rottenstein Law Group ... more than 59,229 complaints since 2004 from women claiming they ... known as the Mirena IUD.* , Among the most common ... ‘expulsion,’ where the IUD came out on its own. There ... News article. “Abdominal pain is also common, with 3,774 complaints. ...

(Date:5/24/2013)... Denver, CO (PRWEB) May 24, 2013 ... SEO analysis, in partnership with JD Media Surge, a ... , The dental SEO analysis service will focus ... high in the search engines for their competitive keywords. ... the dentists website and recommendations based on what their ...

(Date:5/24/2013)... 24, 2013 Gift Card Network ... competitors in sustainable card material, are combining forces ... materials as a sustainable gift card substrate. , ... industry challenges and increase education and usage of ... support the reduction of carbon footprint and environmental ...

(Date:5/24/2013)... 24, 2013 Started in 1982, AMTC’s SHINE ... Orlando. 2013 marks AMTC’s 31st anniversary. SHINE is a ministry ... supermodel Millie Lewis and her daughter, Carey Lewis Arban. , ... casting directors, and music professionals including the New York Film ... Media. They are kings of Hollywood and Christian casting directors. ...

Breaking Medicine News(10 mins):Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2 Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3 Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2 Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2 Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2 Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3 Health News:AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013 2

[0] FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa [0] Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes [0] Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge [0] Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants [0] AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013

... studies that was presented yesterday at Digestive Disease Week? ... compounds can sustain relief for these patients with symptoms ... to review the therapeutic benefits for irritable bowel syndrome ... of the bowel disorders like IBS and Crohn's disease ...

... surgeon Dr Jerome Blanchard who had removed the wrong kidney ... , ,The disciplinary hearing was told yesterday that ... a patient and left her dependent on dialysis, as he ... Blanchard took out his patient’s transplant kidney, which was still ...

... says that each time an elderly person falls at ... two days of crew time.// ,Significant numbers ... suggesting that these facilities are relying on ambulance services ... calls for falls made to the ambulance service in ...

... on 100 soft drinks and beverages by the FDA (Food ... the presence of benzene//, a carcinogen in much higher amount ... ,FDA had alerted these companies, and they had ... done so. Though environmental companies had expressed concern regarding this, ...

... facility for the Medical Linear Accelerator (LINAC) here under ... (DIT). ,The Society for Applied Microwave Electronics ... which pioneered the development of an indigenous Medical LINAC, ... a cost of Rs 24.88 crore, DIT Secretary D ...

... such as gastric bypass and laparoscopic reflux ... reflux// disease respectively, are becoming popular, highlights ... Week, which represents the largest gathering of ... such as gastroenterology, endoscopy, gastrointestinal surgery and ...

Cached Medicine News:Health News:New compounds Help Sustain relief For Patients With Symptoms of Bowel Disorders 2 Health News:New compounds Help Sustain relief For Patients With Symptoms of Bowel Disorders 3 Health News:Consultant Bungles A Kidney Surgery 2 Health News:Soda Drinks Contain Benzene - A Carcinogen, Reports FDA 2 Health News:Soda Drinks Contain Benzene - A Carcinogen, Reports FDA 3 Health News:Gastric Bypass And Laparoscopic Reflux Surgery Gaining Popularity 2 Health News:Gastric Bypass And Laparoscopic Reflux Surgery Gaining Popularity 3

New compounds Help Sustain relief For Patients With Symptoms of Bowel Disorders Consultant Bungles A Kidney Surgery Ambulance Services Cost ?145 Each Time An Elderly Person Sustains A fal Soda Drinks Contain Benzene - A Carcinogen, Reports FDA Medical LINAC Machine Manufacturing Unit At Khargar Gastric Bypass And Laparoscopic Reflux Surgery Gaining Popularity

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

Medicine Products:

Vitamin E, Serum or Plasma Vitamin D, 25-Hydroxy Vitamin B12 & Folate Vitamin B6 (Pyridoxine), Total, Plasma